Search Results - "GREINWALD, R"

Refine Results
  1. 1
  2. 2

    Peripheral blood eosinophils and other non‐invasive biomarkers can monitor treatment response in eosinophilic oesophagitis by Schlag, C., Miehlke, S., Heiseke, A., Brockow, K., Krug, A., Arnim, U., Straumann, A., Vieth, M., Bussmann, C., Mueller, R., Greinwald, R., Bajbouj, M.

    Published in Alimentary pharmacology & therapeutics (01-11-2015)
    “…Summary Background Monitoring of the treatment response in eosinophilic oesophagitis (EoE) requires structured endoscopical and histological examination of the…”
    Get full text
    Journal Article
  3. 3

    Editorial: mesalazine to prevent recurrent acute diverticulitis—the final nail in the coffin. Authors’ reply by Kruis, W., Greinwald, R.

    Published in Alimentary pharmacology & therapeutics (01-08-2017)
    “…Linked ContentThis article is linked to Gracie and Ford et al and Kruis and Greinwald papers. To view these articles visit https://doi.org/10.1111/apt.14180…”
    Get full text
    Journal Article
  4. 4

    Randomised clinical trial: mesalazine (Salofalk granules) for uncomplicated diverticular disease of the colon – a placebo‐controlled study by Kruis, W., Meier, E., Schumacher, M., Mickisch, O., Greinwald, R., Mueller, R.

    Published in Alimentary pharmacology & therapeutics (01-04-2013)
    “…Summary Background Robust evidence regarding medical intervention for symptomatic uncomplicated colonic diverticular disease (DD) is sparse. Aim To investigate…”
    Get full text
    Journal Article
  5. 5

    Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial by Kruis, W, Kiudelis, G, Rácz, I, Gorelov, I A, Pokrotnieks, J, Horynski, M, Batovsky, M, Kykal, J, Boehm, S, Greinwald, R, Mueller, R

    Published in Gut (01-02-2009)
    “…To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine)…”
    Get more information
    Journal Article
  6. 6
  7. 7
  8. 8

    Mesalazine granules are superior to Eudragit‐L‐coated mesalazine tablets for induction of remission in distal ulcerative colitis – a pooled analysis by Leifeld, L., Pfützer, R., Morgenstern, J., Gibson, P. R., Marakhouski, Y., Greinwald, R., Mueller, R., Kruis, W.

    Published in Alimentary pharmacology & therapeutics (01-11-2011)
    “…Aliment Pharmacol Ther 2011; 34: 1115–1122 Summary Background  Different oral formulations of ‘mesalazine (mesalamine)’ may have different efficacy in distal…”
    Get full text
    Journal Article
  9. 9
  10. 10
  11. 11

    Budesonide foam versus budesonide enema in active ulcerative proctitis and proctosigmoiditis by GROSS, V., BAR‐MEIR, S., LAVY, A., MICKISCH, O., TULASSAY, Z., PRONAI, L., KUPCINSKAS, L., KIUDELIS, G., POKROTNIEKS, J., KOVÁCS, Á., FASZCZYK, M., RAZBADAUSKAS, A., MARGUS, B., STOLTE, M., MÜLLER, R., GREINWALD, R.

    Published in Alimentary pharmacology & therapeutics (15-01-2006)
    “…Summary Background  Rectal budesonide is an effective treatment of active ulcerative proctitis or proctosigmoiditis. Aim  To compare the therapeutic efficacy,…”
    Get full text
    Journal Article
  12. 12

    Colonic spread and serum pharmacokinetics of budesonide foam in patients with mildly to moderately active ulcerative colitis by BRUNNER, M., VOGELSANG, H., GREINWALD, R., KLETTER, K., KVATERNIK, H., SCHROLNBERGER, C., EICHLER, H.‐G., BRUNNER, H., DUDCZAK, R., MÜLLER, M.

    Published in Alimentary pharmacology & therapeutics (01-09-2005)
    “…Summary Background : Local treatment with foams in patients suffering from ulcerative proctitis or proctosigmoiditis is considered a rational treatment option…”
    Get full text
    Journal Article
  13. 13
  14. 14

    A double‐blind dose‐escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis by Marakhouski, Y., Fixa, B., Holomán, J., Hulek, P., Lukas, M., Bátovský, M., Rumyantsev, V. G., Grigoryeva, G., Stolte, M., Vieth, M., Greinwald, R.

    Published in Alimentary pharmacology & therapeutics (15-01-2005)
    “…Summary Background : Mesalazine as the treatment standard for ulcerative colitis can be applied in different galenical preparations. Aim : A novel formulation…”
    Get full text
    Journal Article
  15. 15

    6‐Thioguanine — efficacy and safety in chronic active Crohn's disease by Herrlinger, K. R., Kreisel, W., Schwab, M., Schoelmerich, J., Fleig, W. E., Ruhl, A., Reinshagen, M., Deibert, P., Fellermann, K., Greinwald, R., Stange, E. F.

    Published in Alimentary pharmacology & therapeutics (15-02-2003)
    “…Summary Background : Azathioprine and mercaptopurine are commonly used in chronic active Crohn's disease. They share the disadvantage of a delayed onset of…”
    Get full text
    Journal Article
  16. 16

    Thioguanine‐nucleotides do not predict efficacy of tioguanine in Crohn's disease by Herrlinger, K. R., Fellermann, K., Fischer, C., Kreisel, W., Deibert, P., Schoelmerich, J., Fleig, W. E., Ruhl, A., Reinshagen, M., Greinwald, R., Stange, E. F., Schwab, M.

    Published in Alimentary pharmacology & therapeutics (15-06-2004)
    “…Summary Background : 6‐Thioguanine‐nucleotides seem to be the active metabolites of thiopurine therapy, and their monitoring has been considered a useful tool…”
    Get full text
    Journal Article
  17. 17

    Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission by DE JONG, D. J, BAC, D. J, TAN, G, DE BOER, S. Y, GRABOWSKY, I. L. F, JANSEN, J. B. M. J, GREINWALD, R, NABER, T. H. J

    Published in Netherlands journal of medicine (01-10-2007)
    “…In previous trials, budesonide 6 mg/day was able to prolong the time to relapse in patients with quiescent Crohn's disease and budesonide 9 mg/day was…”
    Get full text
    Journal Article
  18. 18

    Feasibility and response to budesonide as topical corticosteroid therapy for acute intestinal GVHD by BERTZ, H, AFTING, M, KREISEL, W, DUFFNER, U, GREINWALD, R, FINKE, J

    Published in Bone marrow transplantation (Basingstoke) (01-12-1999)
    “…Therapy of acute intestinal GVHD is still one of the main challenges after allogeneic transplantation. Increasing systemic immunosuppression (IS) is the first…”
    Get full text
    Journal Article
  19. 19

    Oral Budesonide Significantly Improves Water Absorption in Patients with Ileostomy for Crohn Disease by Ecker, K.-W., Stallmach, A., Seitz, G., Gierend, M., Greinwald, R., Achenbach, U.

    Published in Scandinavian journal of gastroenterology (01-03-2003)
    “…Background: In addition to their anti-inflammatory effects, steroids influence electrolyte and water transport systems in the intestinal mucosa. This study…”
    Get full text
    Journal Article
  20. 20